A SEER-Medicare analysis of the impact of metformin on overall survival in ovarian cancer

No statistically significant association was observed between metformin use and overall survival in a matched cohort of 360 ovarian cancer patients. However, exploratory modeling suggests metformin use may be protective in a certain subgroup of patients.